News

Asians, Hispanics fare best with lupus nephritis–linked end-stage renal disease


 

References

Patients with end-stage renal disease caused by lupus nephritis have a lower risk of death or of experiencing cardiovascular events if they are Asian or and Hispanic, compared with whites and African Americans, Dr. Jose A. Gómez-Puerta and his colleagues wrote in a paper published online Jan. 28 in Arthritis Care & Research.

African Americans also had 27% greater risk of death than did whites in the study, which analyzed a population of more than 12,000 patients enrolled in the U.S. Renal Data System during 1995-2008. This is the first nonacademic, cohort-based study to investigate outcomes among lupus nephritis–linked end-stage renal disease patients by race and ethnicity, the authors said.

Even after researchers adjusted for multiple confounding factors, they found 1-, 5-, and 10-year survival rates were better in Asians than among whites, and in Hispanics than among non-Hispanics, although more research will be needed to determine the exact mechanisms behind the racial gaps. Read the full article at: Arthritis Care & Research (doi:10.1002/acr.22562).

Recommended Reading

IVIG may be worthwhile in treatment of refractory active diffuse scleroderma
MDedge Rheumatology
Rx for specialists: Know how ACA affects patients’ ability to pay for meds
MDedge Rheumatology
Lowest SLE survival rates found in black and Native American patients
MDedge Rheumatology
IPAH patients’ nonresponse to vasodilator challenge linked to poor recruitment of capillary surface
MDedge Rheumatology
Antibody hallmark for lupus challenged by study
MDedge Rheumatology
Lower diabetes risk seen in lupus patients using hydroxychloroquine
MDedge Rheumatology
For lupus nephritis patients, proteinuria is best predictor of renal outcomes
MDedge Rheumatology
High interferon levels related to preeclampsia in pregnant lupus patients
MDedge Rheumatology
Lupus doesn’t predict poor hip or knee arthroplasty outcomes
MDedge Rheumatology
Periostin has potential as biomarker in lupus nephritis
MDedge Rheumatology